Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

225

Enrollment

INDUSTRY

Sponsor class

Stopped After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.

Conditions

Metastatic Melanoma
Squamous Cell Carcinoma of the Head and Neck
Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Lifileucel
BIOLOGICAL: LN-145
DRUG: Pembrolizumab
BIOLOGICAL: LN-145-S1
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Nivolumab-relatlimab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Nab paclitaxel
DRUG: Pemetrexed

Sponsor

Iovance Biotherapeutics, Inc.